lercanidipine / Generic mfg. - LARVOL DELTA

Thiazole-Substituted Benzoylpiperazines with Anti-Cancer and Anti-Inflammatory Activities: Comparative Evaluation with Lercanidipine. (PubMed, Int J Mol Sci) - "Compound 29 showed the highest cytotoxic potency among the tested derivatives and was further evaluated in combination with cisplatin and lercanidipine. These in vitro and in silico findings suggest that p38α MAPK may represent a potential molecular target of Compound 29. Overall, the findings demonstrate the cytotoxic and anti-inflammatory activities of thiazole-substituted benzoylpiperazines and identify Compound 29 as a potent member of this series for further investigation in vitro."

Clinical • Journal • Oncology • CASP3 • CASP8 • TNFA

Diffuse eruptive spider angiomas possibly associated with long-term lercanidipine therapy: A case report. (PubMed, JAAD Case Rep) - No abstract available

Journal

Olaparib-Induced Hypercreatininemia: Cystatin C Prevents Misdiagnosis of Chronic Kidney Disease in an Ovarian Cancer Patient (ERA 2026) - "Her medical history included childhood nephrotic syndrome treated with corticosteroids and cyclophosphamide, with complete remission since adolescence. Cancer treatment comprised neoadjuvant and adjuvant carboplatin/paclitaxel/bevacizumab with cytoreductive surgery, followed by concurrent maintenance with bevacizumab and olaparib 300 mg twice daily...At presentation, edema had resolved following discontinuation of lercanidipine...Of note, olaparib- mediated transporter inhibition may impair elimination of other drugs; metformin accumulates significantly due to reduced MATE1/2-K activity...The case is particularly instructive given the patient's cumulative nephrotoxic burden and remote history of nephrotic syndrome, which heightened clinical suspicion for true kidney injury. This report underscores the importance of cystatin C measurement in oncology patients receiving olaparib and highlights the risk of undertreating cancer based on misleading creatinine elevations."

Clinical • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Glomerulonephritis • High Grade Serous Ovarian Cancer • Metabolic Disorders • Nephrology • Oncology • Ovarian Cancer • Renal Disease • Solid Tumor • CST3

Nitrosamine-related phototoxicity/photocarcinogenicity, drug contamination and melanoma development: facts and/or controversies based on two new cases (EADV-Sp 2026) - "Materials and Methods We present two consecutive patients with melanomas who developed them against the background of taking a potentially/actually nitrosamine-contaminated medication: 1) in patient 1 (Fig.1a-d), the medications were valsartan, nebivolol, and hydrochlorothiazide, each of which is available on the FDA list for possible photo/ carcinogen contamination, and 2) in patient 2 (Fig.1e), the patient developed melanoma on a background of taking bisoprolol, metformin, and lercanidipine. The first step toward a solution is acknowl- edging the problem. The current issue is evident and necessitates acknowledgment through careful observation and analysis of the clinicopathological correlations."

Clinical • Melanoma • Skin Cancer • Solid Tumor

Shark pedicle island flap for basal cell carcinoma of the perialar zone of the nose: photoxicity and photocarcinogenicity mediated by the intake of potentially nitrosamine contaminated drugs  -a possible new explanation for the skin cancers pathogenesis (EADV-Sp 2026) - "Results We inform about another polymedication intake in a patient with arterial hypertension and diabetes mellitus, which includes the following medications: gliclazide 60 mg once daily and metformin hydrochloride 850 mg once daily, both since 24 years ; sotalol hydrochloride 80 mg since 2 years; bisoprolol fumarate 5 mg since 17 years; candesartan cilexetil/hydrochlorothiazide 16 mg/ 12.5 mg since 2 years; and lercanidipine hydrochloride 20 mg also since 2 years. This article focuses on the possible role of drug-mediated photo nitrosogenesis/ carcinogenesis of skin cancer by briefly reviewing and analyzing the available literature to date. Figure 3: 1 month follow-up"

Basal Cell Carcinoma • Diabetes • Genetic Disorders • Metabolic Disorders • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer

Targeting the US21 viroporin of human cytomegalovirus by calcium channel blockers as a new antiviral strategy. (PubMed, Curr Res Microb Sci) - "Four dihydropyridine compounds (azelnidipine, efonidipine, lercanidipine, and niguldipine) were selected from 249 Calcium Channel Blockers (CCBs) in the DrugBank database. Finally, drug combination studies revealed synergistic interactions between CCBs and maribavir treatment. Together, these findings support the hypothesis that clinically used CCBs may target pUS21 viroporin activity and hamper HCMV replication, thus offering a novel and promising antiviral strategy against HCMV, including drug-resistant strains."

Journal • Cytomegalovirus Infection

Lercanidipine-associated peripheral oedema after pristinamycin introduction: A pharmacokinetic interaction hypothesis. (PubMed, Therapie) - No abstract available

Journal • PK/PD data

Nephroprotective effect of lercanidipine against gentamicin-induced kidney damage. (PubMed, J Adv Pharm Technol Res) - "Lercanidipine also markedly attenuated oxidative stress, reducing MDA by about 65% and increasing SOD and GSH activities by approximately 183% and 140%, respectively, relative to gentamicin alone. These findings demonstrate that lercanidipine significantly protects against gentamicin-induced nephrotoxicity by improving renal function, restoring electrolyte homeostasis, and enhancing the antioxidant defence system."

Journal • Nephrology • Renal Disease

Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers. (PubMed, Clin Pharmacol Drug Dev) - "The geometric mean ratios and 90% confidence intervals of Cmax, AUC0-t, and AUC0-∞ for the test formulation relative to the reference formulation were 110.37% (99.96%-121.86%), 106.81% (99.65%-114.49%), and 106.91% (99.86%-114.45%), respectively, all within the range of 80.00%-125.00%. The test formulation met the bioequivalence acceptance criteria and was well tolerated by healthy Chinese volunteers under fasting conditions."

Journal • PK/PD data • Cardiovascular • Hypertension

Capillary blood microsampling and LC-Orbitrap analysis for adherence monitoring of cardiovascular drugs: method development, cross-validation, and patient proof-of-concept using VAMS and Capitainer-B. (PubMed, Talanta) - "Amlodipine, atenolol, atorvastatin, bisoprolol, carvedilol, clopidogrel, diltiazem, lercanidipine, metoprolol, nebivolol, prasugrel, rosuvastatin, salicylic acid, simvastatin hydroxy acid, and verapamil were included. In a proof-of-concept involving 30 patients, finger-prick concentrations from VAMS and Capitainer-B were interchangeable, supporting the suitability of these adherence workflows but reference ranges for capillary blood remain necessary to enable routine clinical interpretation. In summary, this work established a reliable, LC-Orbitrap-based microsampling platform for monitoring adherence and identified stability issued amongst others that guide future method selection and development."

Journal • Cardiovascular

QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals. (PubMed, BMC Chem) - "A rapid, sensitive, and selective reversed-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous determination of five dihydropyridines calcium channel blockers, namely: amlodipine (AML), nifedipine (NIF), lercanidipine (LER), nimodipine (NIM) and nitrendipine (NIT) using Quality by Design approaches (QbD). The validated method was successfully applied for the determination of these drugs in their pharmaceutical formulations, with recovery values ranging from 99.57 to 100.07% and without significant interference from excipients. Greenness and practicality evaluations detected using AGREE, MoGAPI, complex MoGAPI, AGSA, CaFRI, BAGI and CACI tools which were, indicating the method's environmental friendliness and excellent practical applicability for routine pharmaceutical quality control analysis."

Journal • Acute Myelogenous Leukemia

Evaluation the inhibitory effect of nicardipine on the metabolism of quetiapine. (PubMed, Front Pharmacol) - "In vitro, two incubation systems of rat liver microsomes (RLM) and human liver microsomes (HLM) were established and optimized to explore potential interactions between five kinds CCBs (nicardipine, dilthiazem, lercanidipine, nimodipine, nitrendipine), five kinds antihypertensive TCM (quercetin, fangchinoline, apigenin, tetrandrine, and berberine) and quetiapine, and to evaluate their underlying inhibition mechanisms. In vivo results indicated that nicardipine could significantly increase the main pharmacokinetic parameters AUC(0-t), , and Cmax of quetiapine, but decrease the AUC(0-t) of its metabolite N-desalkylquetiapine. The findings of this study suggested that nicardipine had inhibited the metabolism of quetiapine, suggesting the dose adjustment or therapeutic drug monitoring of quetiapine should be conducted to achieve individualized therapy."

Journal

Cytogenotoxic Evaluation of Lercanidipine Hydrochloride in Human Lymphocytes Using Micronucleus, Chromosome Abnormalities, and Molecular Docking Assays. (PubMed, Cell Biol Int) - "By contrast, the positive control, mitomycin C (MMC), binds to the major groove via intercalation, forming covalent cross-links, with a binding energy of -5.45 kcal/mol. Overall, these findings suggest that LHC primarily exhibits cytotoxic effects (e.g., inhibition of DNA replication or transcription), with only limited and preliminary evidence of genotoxic potential. Further studies are needed to elucidate the safety of LHC and its DNA interaction mechanisms."

Journal • Oncology

Case-based evaluation of a digital timeline tool for drug causality assessment in skin eruptions (EADV 2025) - " The digital timeline identified five drugs with temporally compatible exposure: rilmenidine, diosmectite, enoxaparin, lercanidipine, and the combination perindopril/indapamide. This case highlights the potential benefit of digital tools in standardizing the visualization of medication histories for suspected drug-induced skin reactions. Digitalization of causality assessment processes may enhance diagnostic accuracy and workflow efficiency in complex clinical scenarios."

Clinical • Immunology

Drug-Induced Cutaneous Vasculitis: A Report of Three Cases (EADV 2025) - "Case2 A 44-year-old man, hospitalized for an ankle fracture, developed palpable purpura on his upper and lower limbs seven days after starting cefotaxime and ciprofloxacin...The implicated agents—lercanidipine, cephalosporins, fluoroquinolones, adalimumab—illustrate the wide pharmacologic range of potential triggers. In any recent-onset cutaneous vasculitis, drug-induced causes should be systematically considered and assessed through clinical evolution after withdrawal of the suspected agent."

Clinical • Acute Kidney Injury • Cardiovascular • Crohn's disease • Diabetes • Endocrine Disorders • Eosinophilia • Fibrosis • Gastroenterology • Hypertension • Infectious Disease • Inflammatory Bowel Disease • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Renal Disease • Vasculitis

Beta-blocker side-effects in clinical practice: a nationwide approach (ESC-WCC 2025) - "The predominantly prescribed BBs were metoprolol (76%), propranolol (7%), carvedilol (6%), and bisoprolol (6%), whereas amlodipine (84%) and lercanidipine (11%) constituted the majority of the CCB group. (Figure 2) Conclusions In a large nationwide cohort, the incidence of BB side-effects was clinically relevant and consistently increased compared with CCBs with the exception of erectile dysfunction. These findings are exceptionally clinically relevant and surprising as erectile dysfunction is often the most prevalent concern for male patients when initiating BB treatment."

Adverse events • Clinical • Cardiovascular • Hypertension

Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease. (PubMed, Curr Med Res Opin) - "In the present narrative review, we aimed to specifically describe the cardiorenal protective effects of dihydropyridine CCBs (particularly lercanidipine and manidipine, based on the available evidence) and non-dihydropyridine CCBs (verapamil and diltiazem). With regard to this research topic, we also reviewed the 2023 European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension [endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)] and the 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiomyopathies. Finally, we proposed practical criteria for prescribing the most appropriate CCB (among dihydropyridine CCBs and non-dihydropyridine CCBs) for patients with hypertension and proteinuric CKD (with or without diabetes) in different clinical settings."

Journal • Review • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

Lercanidipine-Induced Hyponatremia in Elderly Patients: A Not-So-Rare Complication. (PubMed, Cureus) - "Current NHS guidelines do not recommend routine electrolyte monitoring when prescribing CCBs, unlike recommendations for ACE inhibitors and ARBs. We recommend implementing routine electrolyte monitoring when initiating CCBs in this vulnerable population group to prevent potentially life-threatening complications."

Journal • Cardiovascular • Critical care • Geriatric Disorders • Heart Failure • Hypertension

SKIN-CKD: The Role of Skin Sodium Accumulation in Chronic Kidney Disease (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

New trial • Chronic Kidney Disease • Nephrology • Renal Disease

Management of Lercanidipine-induced Lyell's syndrome (Euroanaesthesia 2025) - "Pain was managed with patient-controlled analgesia of Morphine, Ketamine and Droperidol plus peripheral analgesia. Hydrotherapy sessions were provided with a combination of Propofol, Ketamine, Dexmedetomidine, and Fentanyl, allowing effective wound care.Patient care involved daily ophthalmology evaluation, pulmonary rehabilitation and oxygen therapy. By the 24th day of hospitalization, the patient showed over 90% healing of the affected skin areas and was discharged home. This case underscores the critical importance of intensive and rigorous care in the management of TEN, particularly in a specialized BU. Rapid disease progression shows the unpredictable nature of this severe drug-induced reaction."

Inflammation • Ophthalmology • Pain • Rare Diseases • Steven-Johnson Syndrome

Lercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition. (PubMed, Pharmaceuticals (Basel)) - "It also significantly inhibited MAPK signaling, activated apoptotic caspases, and reduced TNF-α levels, suggesting potential anti-inflammatory activity. These findings highlight lercanidipine's potential for repurposing as an adjunct in cancer therapy."

Journal • Breast Cancer • Cardiovascular • Genito-urinary Cancer • Neuroblastoma • Oncology • Prostate Cancer • Solid Tumor • CASP3 • CASP8 • TNFA

Nonsurgical management of pheochromocytoma in the very elderly – a case series and review of the literature (ESPE-ESE 2025) - "Blood pressure (BP) treatment was with doxazosin, losartan and bisoprolol...On a follow up of 0.54 years BP was slightly elevated and was controlled with doxazosin, lercanidipine and bisoprolol... in this series of three elderly patients with PCC that did not have an adrenalectomy we found one occurrence of a stroke and one death in the same patient on an average follow up of 5.69 years. It thus seems that medical management may allow satisfactory disease control in select cases in which surgery is not possible or refused by very elderly patients."

Clinical • Review • Cardiovascular • Endocrine Cancer • Oncology • Solid Tumor

Warning issued over common blood pressure drug after labelling error (MSN News) - "Patients who take a common drug for high blood pressure are being urged to check the medication after its manufacturer reported that a mistake in the strength of the dose had been printed on some packs...One batch of the medicine Lercanidipine, made by Recordati Pharmaceuticals, is labelled as containing 10mg tablets when it in fact contains 20mg....The correct strength is printed on the top of the carton and on the blister strips, according to an alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA)...Patients are being urged to check for the batch number MD4L07 with an expiry date of January 2028 as a 'precautionary measure'."

Commercial • Hypertension

Voltammetric determination of lercanidipine in urine, blood plasma, and serum using hollow fiber-based liquid phase microextraction. (PubMed, Talanta) - "The calibration dependence of the combined HF-LPME-SWV method was established in the range of 1-1000 nmol L-1, with limits of quantification (LOQ) and detection (LOD) of 3.3 and 1.1 nmol L-1, respectively. The applicability of the developed method was verified by analysis of human urine, blood plasma, and blood serum samples spiked with 20 and 100 nmol L-1 LCN with recoveries ranging from 93.2 to 112.9 % with respective RSDs 1.72-8.5 % (n = 3)."

Journal

Looks are deceiving: An uncommon cause of milky white peritoneal dialysis effluent. (PubMed, Perit Dial Int) - "We suspended lercanidipine and within a few days the peritoneal dialysis effluent was clear. Currently the patient is well adjusted to the technique and had no further episodes of chyloperitoneum."

Journal • Dyslipidemia • Hypertriglyceridemia